Nuvation Bio Reports Full Year 2020 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB) reports strong financial results and an optimistic outlook following its merger with Panacea Acquisition Corp. in February 2021.
The company holds approximately $830 million in cash and is focused on advancing its oncology pipeline.
Currently, it is conducting a Phase 1/2 study of its lead compound, NUV-422, which has received FDA's Orphan Drug Designation for malignant gliomas.
Nuvation Bio expects to submit up to five additional Investigational New Drug applications by 2026.
- Strong cash position of approximately $830 million after the merger.
- Initiated Phase 1/2 study of NUV-422 in high-grade gliomas.
- FDA granted Orphan Drug Designation for NUV-422.
- Net loss increased to $41.7 million in 2020, up from $33.6 million in 2019.
- R&D expenses rose to $32.6 million in 2020 from $25.1 million in 2019.
NEW YORK, March 11, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the year ended December 31, 2020 and provided a business update.
"Nuvation Bio began a new chapter as a public company following the successful completion of our business combination with Panacea in February. With a strong cash position of approximately
Recent Business Highlights
- Debuted as publicly traded oncology company following the closing of a business combination with Panacea Acquisition Corp. In February 2021, Nuvation Bio announced the closing of its business combination with Panacea Acquisition Corp., a SPAC sponsored by EcoR1 Capital, and the commencement of trading shares of the combined company on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB." Nuvation Bio's total cash position at closing was approximately
$830 million after transaction costs, including approximately$646 million held in Panacea's trust account and received in concurrent private financings led by EcoR1 Capital, as well as 683 Capital, Ally Bridge Group, Avidity Partners, Deerfield Management Company, Irving Investors, Monashee Investment Management LLC, OrbiMed, Wellington Management and other existing Nuvation Bio shareholders including The Baupost Group, Boxer Capital of the Tavistock Group, Fidelity Management & Research Company, LLC, Omega Funds, Perceptive Advisors, Redmile Group and Surveyor Capital (a Citadel Company). - Initiated a Phase 1/2 study of NUV-422, the first of Nuvation's six compounds to enter the clinic. In December 2020, Nuvation Bio commenced patient enrollment and dosing in the Phase 1/2 study of its lead investigational compound, NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, in adult patients with recurrent or refractory high-grade gliomas, including glioblastoma multiforme (GBM). The Phase 1 dose escalation part of the study is designed to evaluate safety and tolerability, as well as to determine a recommended Phase 2 dose based on the tolerability profile and pharmacokinetic properties of NUV-422. The Phase 2 dose expansion part of the study is expected to initially focus on patients with high-grade gliomas and is designed to evaluate overall response rate, duration of response and survival. Data from the Phase 1 portion of this study is expected in 2022. The U.S. Food and Drug Administration (FDA) in March granted Orphan Drug Designation to NUV-422 for the treatment of malignant gliomas.
- Expanded executive team with key appointments. In January 2021, Nuvation Bio appointed Lisa DeLuca as senior vice president, regulatory affairs. Ms. DeLuca brings more than 25 years of regulatory experience to Nuvation Bio and most recently led the regulatory team at Radius Health. In October 2020, Nuvation Bio appointed Jennifer Fox as chief financial officer to lead corporate strategy, business development, investor relations and corporate communications. Ms. Fox joined Nuvation Bio from Citigroup, where she most recently served as a managing director and co-head of the Healthcare Corporate and Investment Banking Group.
Full Year 2020 Financial Results
The following financial results for the year ended December 31, 2020 represent Nuvation Bio Inc. (now known as Nuvation Bio Operating Company Inc.) as a standalone private company, as its business combination with Panacea Acquisition Corp. closed on February 10, 2021. The financial results of Panacea Acquisition Corp. for the year ended December 31, 2020 will be reported in the Annual Report on Form 10-K to be filed by Nuvation Bio in March 2021. Nuvation Bio's financial statements for the first quarter of 2021, to be reported in May 2021, and for subsequent periods will reflect the financial results of the combined public company.
Research and development expense for the year ended December 31, 2020 was
Net loss for 2020 was
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.
Forward Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential therapeutic benefit of Nuvation Bio's product candidates and the expected timing of clinical trial data. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Nuvation Bio. These forward-looking statements are subject to a number of risks and uncertainties, including those factors discussed in the proxy statement/prospectus filed with the SEC on January 20, 2021, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file, with the SEC. If any of these risks materialize or Nuvation Bio's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Nuvation Bio does not presently know, or that Nuvation Bio currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Nuvation Bio's expectations, plans or forecasts of future events and views as of the date of this press release. Nuvation Bio anticipates that subsequent events and developments will cause Nuvation Bio's assessments to change. However, while Nuvation Bio may elect to update these forward-looking statements at some point in the future, Nuvation Bio specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nuvation Bio's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Nuvation Bio Investor Contact:
ir@nuvationbio.com
Nuvation Bio Media Contact:
Argot Partners
Leo Vartorella
leo@argotpartners.com
NUVATION BIO INC. and Subsidiaries | ||||
Consolidated Balance Sheets (In thousands, except share and per share data) | ||||
December 31, | 2020 | 2019 | ||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | ||||
Prepaid expenses | 914 | 187 | ||
Marketable securities available-for-sale, at fair value | 185,997 | 112,893 | ||
Investments to be held to maturity, at cost | — | 2,508 | ||
Interest receivable on marketable securities | 1,092 | 828 | ||
Deferred financing costs | 2,925 | — | ||
Total current assets | 220,683 | 119,885 | ||
Property and equipment, net | 688 | 646 | ||
Other assets: | ||||
Lease security deposit | 421 | 421 | ||
Total assets | ||||
Liabilities, redeemable convertible preferred stock, and stockholders' deficit | ||||
Current liabilities: | ||||
Accounts payable | ||||
Accrued expenses | 4,380 | 1,163 | ||
Deferred rent | — | 11 | ||
Total current liabilities | 6,551 | 3,204 | ||
Deferred rent - non current | 157 | — | ||
Total liabilities | 6,708 | 3,204 | ||
Redeemable Series A convertible preferred stock, | ||||
360,500,000 shares authorized; 347,423,117 and 184,501,999 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively (liquidation preference of | 267,521 | 141,864 | ||
Stockholders' deficit | ||||
Class A and Class B common stock and additional paid in capital, | 21,961 | 9,759 | ||
Accumulated deficit | (75,955) | (34,296) | ||
Accumulated other comprehensive income | 1,557 | 421 | ||
Total stockholders' deficit | (52,437) | (24,116) | ||
Total liabilities, redeemable convertible preferred stock, and stockholders' deficit | ||||
NUVATION BIO INC. and Subsidiaries | |||
Consolidated Statements of Operations and Comprehensive Loss | |||
(In thousands, except share and per share data) | |||
For the Years Ended December 31, | 2020 | 2019 | |
Operating expenses: | |||
Research and development | $ 32,603 | $ 25,106 | |
General and administrative | 10,948 | 6,993 | |
Total operating expenses | 43,551 | 32,099 | |
Loss from operations | (43,551) | (32,099) | |
Other income (expense): | |||
Interest income | 1,945 | 1,287 | |
Investment advisory fees | (271) | (135) | |
Realized gain on marketable securities | 218 | 53 | |
Interest expense | - | (2,658) | |
Total other income (expense) | 1,892 | (1,453) | |
Loss before income taxes | (41,659) | (33,552) | |
Provision for income taxes | - | - | |
Net loss | $ (41,659) | $ (33,552) | |
Deemed dividend related to beneficial conversion feature and accretion | |||
of discount on Redeemable Series A Convertible Preferred Stock | $ (22,622) | - | |
Net loss attributable to common stockholders | $ (64,281) | $ (33,552) | |
Net loss per share attributable to common stockholders, basic and diluted | $ (0.23) | $ (0.16) | |
Weighted average common shares outstanding, basic and diluted | 277,529,317 | 206,672,024 | |
Comprehensive loss: | |||
Net loss | $ (41,659) | $ (33,552) | |
Other comprehensive income, net of taxes: | |||
Change in unrealized gain on available-for-sale securities | 1,136 | 421 | |
Comprehensive loss | $ (40,523) | $ (33,131) | |
View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvation-bio-reports-full-year-2020-financial-results-and-provides-business-update-301246091.html
SOURCE Nuvation Bio, Inc.
